Provided by Tiger Trade Technology Pte. Ltd.

Biogen

216.65
-1.8500-0.85%
Post-market: 216.650.00000.00%19:45 EDT
Volume:831.00K
Turnover:180.43M
Market Cap:31.99B
PE:38.48
High:218.89
Open:216.47
Low:213.58
Close:218.50
52wk High:222.85
52wk Low:133.53
Shares:147.64M
Float Shares:147.31M
Volume Ratio:1.48
T/O Rate:0.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.63
EPS(LYR):8.79
ROE:4.58%
ROA:5.21%
PB:1.70
PE(LYR):24.65

Loading ...

H.C. Wainwright Remains a Buy on Biogen (BIIB)

TIPRANKS
·
Jul 02

Biogen Says Research, Milestone Charges to Reduce Earnings in Q2, Q3

MT Newswires Live
·
Jul 02

Biogen Inc. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Jul 02

Biogen says Q2 results to include $164M expense on a pre-tax basis

TIPRANKS
·
Jul 02

Biogen Expects Q2 Acquired Ipr&d, Upfront and Milestone Expense of About $164 Million, Hits EPS by $0.95

Reuters
·
Jul 02

Biogen Inc Q3 Shr View $3.98

THOMSON REUTERS
·
Jul 02

Biogen - Expects Q2 2026 $164 Mln Bought In-process R&D, Upfront and Milestone Expense - SEC Filing

THOMSON REUTERS
·
Jul 02

Biogen - Anticipates Q3 2026 Net Income Per Adj Diluted Share Impact of $1.75-$1.95 - SEC Filing

THOMSON REUTERS
·
Jul 02

Health Rounds: Old Cancer Drug May Help Restore Fertility for Certain Women

Reuters
·
Jul 01

Needham Adjusts Price Target on Biogen to $256 From $255, Maintains Buy Rating

MT Newswires Live
·
Jun 29

Biogen to Present Phase 2 CELIA Data for Tau-targeting Alzheimer’s Drug Diranersen at AAIC 2026

Reuters
·
Jun 29

Biogen is Maintained at Buy by Needham

Dow Jones
·
Jun 29

Biogen : Needham Raises Target Price to $256 from $255

THOMSON REUTERS
·
Jun 29

U.S. Research Roundup-3m Co, Nike, Primoris Services

Reuters
·
Jun 29

Biogen (BIIB) Is Up 9.9% After US$1 Billion RayThera Deal And Salanersen Win - Has The Bull Case Changed?

Simply Wall St.
·
Jun 29

Biogen (BIIB) Is Betting Its Next Phase Of Growth On Four New Drugs

Simply Wall St.
·
Jun 27

Biogen Inc. Stock Advances 7.0%, Outperforms Peers

Dow Jones
·
Jun 27

Movement Alert|Biogen Rises 5.86% in Regular Trading, Suspends Most Legacy Apellis Research Programs to Focus on Core Pipeline

Market Focus
·
Jun 26

Early notable gainers among liquid option names on June 26th

TIPRANKS
·
Jun 26

Biogen Scales Back Apellis Programs, Trims Research Roles After $5.6 Billion Buyout

Reuters
·
Jun 26